Adage Capital Partners’s Arcus Biosciences RCUS Stock Holding History

Adage Capital Partners’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-152,000	Closed	-$2.07M	–	990
2025 Q3	$2.07M	Buy	+152,000	New	+$1.58M	﹤0.01%	805
2025 Q1	–	Sell	-443,000	Closed	-$6.6M	–	922
2024 Q4	$6.6M	Buy	+443,000	New	+$7.23M	0.01%	679
2022 Q2	–	Sell	-75,000	Closed	-$2.37M	–	1134
2022 Q1	$2.37M	Hold	75,000	–	–	﹤0.01%	886
2021 Q4	$3.04M	Hold	75,000	–	–	0.01%	852
2021 Q3	$2.62M	Hold	75,000	–	–	0.01%	881
2021 Q2	$2.06M	Sell	75,000 -175,000	-70%	-$5M	﹤0.01%	879
2021 Q1	$7.02M	Hold	250,000	–	–	0.01%	758
2020 Q4	$6.49M	Hold	250,000	–	–	0.01%	660
2020 Q3	$4.29M	Hold	250,000	–	–	0.01%	658
2020 Q2	$6.18M	Buy	+250,000	New	+$6.75M	0.02%	591

Other funds holding RCUS

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Adage Capital Partners's RCUS Position: Q4 2025 in Review

Adage Capital Partners sold out of Arcus Biosciences (RCUS) in Q4 2025, closing a stake of 152,000 shares — an estimated $2.07M sold.

Adage Capital Partners first reported a position in RCUS in Q2 2020 and held it in 10 quarters. The position peaked at $7.02M in Q1 2021. 209 funds tracked by Wall St. Rank hold RCUS as of Q4 2025.

Adage Capital Partners reported no remaining Arcus Biosciences position as of Q4 2025 after selling out during the quarter.
Adage Capital Partners sold 152,000 Arcus Biosciences shares in Q4 2025, an estimated $2.07M.
Adage Capital Partners first reported a position in Arcus Biosciences in Q2 2020 and held it in 10 quarters.
Adage Capital Partners's Arcus Biosciences position peaked at $7.02M in Q1 2021.
209 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2025.

Based on Adage Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.